Oncoceutics has a robust pipeline based on ONC201, ONC201 analogs and investigational portfolios that are in various stages of development.  The most advanced of these – ONC201 is currently in six clinical trials – a Phase I trial with an expansion cohort in solid tumors at the Rutgers Cancer Institute of NJ, a Phase II glioblastoma trial at Massachusetts General Hospital, two Phase I/II trials in Non-Hodgkin’s Lymphoma and acute leukemias at the MD Anderson Cancer Center, and two trials at Fox Chase Cancer Center; one Phase I/II trial in multiple myeloma and one Phase I trial in solid tumors and multiple myeloma. The current trials will treat more than 150 patients through 2017.

Oncoceutics’ Pipeline (May 2017)

Pipeline 5.2.17